Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort - Summary - MDSpire

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

  • By

  • Augustin Boudry

  • Laurène Fenwarth

  • Raphaël Itzykson

  • Thorsten Braun

  • Lionel Adès

  • Élise Fournier

  • Céline Berthon

  • Delphine Lebon

  • Stéphane De Botton

  • Régis Peffault de Latour

  • Cécile Pautas

  • Hervé Dombret

  • Emmanuel Raffoux

  • Claude Gardin

  • Karine Celli-Lebras

  • Claude Preudhomme

  • Nicolas Duployez

  • May 28, 2026

  • 0 min

Share

Objective:

To explore the clinical relevance of ultra-high-sensitivity next-generation sequencing (UHS-NGS) for measurable residual disease (MRD) assessment in older patients with acute myeloid leukemia (AML).

Key Findings:
  • UHS-NGS MRD was detectable in 52.7% of patients post-IDAC.
  • MRD positivity correlated with higher 2-year cumulative incidence of relapse (CIR 73% vs 38%), inferior relapse-free survival (RFS 23% vs 55%), and reduced overall survival (OS 54% vs 79%).
  • Patients with multiple myelodysplasia-related gene (MRG) mutations had significantly worse outcomes compared to those with a single mutation.
Interpretation:

Limitations:
  • The study's findings are based on a specific cohort and may not be generalizable to all older AML patients.
  • Limited data on patients without available post-IDAC samples.
Conclusion:

Original Source(s)

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

  • by Augustin Boudry, Laurène Fenwarth, Raphaël Itzykson, Thorsten Braun, Lionel Adès, Élise Fournier, Céline Berthon, Delphine Lebon, Stéphane De Botton, Régis Peffault de Latour, Cécile Pautas, Hervé Dombret, Emmanuel Raffoux, Claude Gardin, Karine Celli-Lebras, Claude Preudhomme, Nicolas Duployez

  • May 28, 2026

Related Content

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

FOXA2 in cancer: from fundamental biology to clinical translation

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2